389P Updated efficacy and safety of pralsetinib in Chinese patients with advanced RET fusion+ non-small cell lung cancer

Abstract

Pralsetinib is a potent, selective Rearranged during Transfection (RET) inhibitor targeting oncogenic RET alterations and is the first RET inhibitor approved in China. ARROW is a global phase I/II registrational study to evaluate the safety and efficacy of pralsetinib in a variety of advanced RET altered solid tumors including non-small cell lung cancer (NSCLC). Here we present updated results of the ARROW study in Chinese patients with advanced RET fusion+ NSCLC.